Introduction
Incidence of type 2 diabetes is rapidly increasing worldwide. Most anti-diabetic drugs cannot be used in patients with preexisting liver, kidney and heart disease, making treatment of type 2 diabetes complicated. Drugs that can both lower blood glucose level and reduce diabetes related complications would be ideal. There have been several promising small clinical studies on the use of natural products as antidiabetic agents.
Abstract Small clinical studies have shown that oral treatment with the plant alkaloid berberine (BBR) reduces blood glucose levels similar to that of metformin and have promoted its use as a novel anti-diabetic therapy. However, in vitro studies have shown that high concentrations of BBR potently inhibit cell proliferation through inhibition of mitochondrial function. Cardiolipin (Ptd 2 Gro) is a key phospholipid required for regulating mitochondrial bioenergetic function. We examined if BBR inhibited oxygen consumption rate in H9c2 cardiac myocytes through alteration in Ptd 2 Gro metabolism. Treatment of H9c2 cells with BBR resulted in a rapid (within minutes) concentration-dependent decrease in the oxygen consumption rate (OCR) as determined using a Seahorse XF24 analyzer. Concentrations of BBR as low as 1 µM were effective in inhibiting OCR. In addition, all concentrations of BBR inhibited the fatty acidmediated increase in OCR that was observed in untreated cells. Treatment of H9c2 cells with up to 25 µM BBR for 24 h markedly reduced [ 3 H]thymidine incorporation into Berberine (BBR) is a natural compound found in the roots, stems and bark of many different plants (reviewed in [1] ). It has been used for centuries in China as a traditional medicine. Oral treatment of diabetic patients with BBR was shown to reduce blood glucose levels similar to that of metformin. BBR may mediate this effect on glucose lowering through activation of adenosine 5′-monophosphate kinase. Other studies in animal models of diabetes suggest that BBR may have a beneficial effect in reducing diabetes related complications (reviewed in [1] ). Thus, BBR may exhibit promise as an oral medication for type 2 diabetes and diabetes related complications. However, recent in vitro studies have indicated that BBR may also be a potent inhibitor of cell proliferation through reduced mitochondrial oxygen consumption mediated via inhibition of Complex I [2] [3] [4] . Currently, there are no well-controlled, long-term clinical trials to evaluate BBRs effectiveness and safety on mitochondrial function.
Cardiolipin (Ptd 2 Gro) is a key mitochondrial membrane phospholipid required for mitochondrial energy metabolism and assembly of mitochondrial respiratory complexes (reviewed in [5, 6] ). In this study we examined if BBR altered mitochondrial oxygen consumption rate in H9c2 cardiac myocytes through alteration in Ptd 2 Gro metabolism. 
Materials and Methods

Materials
Cell Culture
H9c2 cardiomyoblasts cells were cultured in 60 mm culture dishes and passed in 4 ml Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS, and 1× antibiotic/antimycotic. Before experiments, the medium was removed and 4 ml differentiation medium (DMEM with 1% FBS and 1 μM retinoic acid) was added to the cells. The medium was replaced every 48 h for 6 days.
Differentiation into cardiomyocytes was confirmed by expression of beta myosin heavy chain as previously described [7] .
Determination of Ptd 2 Gro Synthesis
Where indicated, cell culture media was supplemented with 0.1 mM [1- 14 C]palmitate:BSA (1:1 molar ratio) (5 μCi/dish) or 0.1 mM [1-
14 C]oleate:BSA (1:1 molar ratio) (5 μCi/dish) and incubated with up to 50 μM BBR for 24 h. Under all conditions examined > 95% of cells excluded Trypan blue after 24 h incubation with BBR. Subsequent to incubation, cells were washed twice with ice cold PBS and harvested with 2 ml of methanol:H 2 O (1:1, by vol) and 10 μl aliquots removed for protein determination and total uptake of radioactivity. Lipids were extracted by addition of chloroform:methanol:H 2 O (2:1:1.5, by vol). The organic phase was removed "dried under N 2 ″ and resuspended in chloroform:methanol (2:1, by vol). Ptd 2 Gro was separated from other phospholipids by two-dimensional thin-layer chromatography and radioactivity incorporated into Ptd 2 Gro determined as previously described [8] . Silica gel corresponding to Ptd 2 Gro standards was removed and placed in a scintillation vial with 5 ml aqueous counting scintillant and radioactivity determined in a Beckman scintillation counter. [1- 14 C] Palmitate and [1-
14 C]oleate incorporation into Ptd 2 Gro were expressed as specific radioactivity of Ptd 2 Gro, that is, activity per quantity of a radionuclide incorporated at each time point.
Other Determinations
For determination of PKCδ association with membranes, H9c2 cells were incubated with 0.1 mM palmitate:BSA (1:1 molar ratio) in the absence or presence of 25 μM BBR for 24 h. The medium was removed, membrane lysates prepared and Western blot analysis performed using anti-PKC antibody as previously described [7] . Protein was determined by the Bio-Rad Bradford protein assay (Mississauga, ON, Canada), M protein assay kit. Phospholipid phosphorus mass of Ptd2Gro was determined as described [8] . Oxygen consumption rate (OCR) was measured from H9c2 cells using a Seahorse Bioscience instrument as previously described [9] . For [
Results
BBR Treatment Rapidly Inhibits OCR in H9c2 Cardiac Myocytes
BBR has been shown to inhibit mitochondrial respiratory function through inhibition of Complex I [2, 3] . We initially examined if BBR altered mitochondrial OCR in differentiated H9c2 cells. H9c2 cells were incubated with various concentrations (0-100 µM) of BBR and OCR determined in a Seahorse XF24 analyzer. BBR addition to H9c2 cells resulted in a rapid (within minutes) reduction in OCR in a concentration dependent manner compared to control cells (Fig. 1a, b) . As little as 1 µM BBR rapidly inhibited H9c2 cellular OCR. We repeated this experiment to determine if BBR altered fatty acid mediated OCR. Incubation of H9c2 cells with oleate stimulated OCR in H9c2 cells (Fig. 1c) . Pre-treatment of H9c2 cells with all concentrations of BBR tested inhibited the oleate-mediated increase in OCR. Concentrations of 25 and 50 µM resulted in maximum inhibition. Thus, BBR treatment inhibits OCR and fatty acid-mediated OCR in H9c2 cells. (Fig. 2a) (Fig. 2b) . BBR treatment reduced Ptd 2 Gro synthesis from [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]oleic acid at 12.5 and 25 µM concentrations (Fig. 2c ) and increased Ptd 2 Gro synthesis from [1- 14 C]palmitic acid at 12.5 µM concentration (Fig. 2e) . In addition, BBR treatment did not alter [1- 14 C]oleic acid or [1-14 C]palmitic acid uptake into H9c2 cells (Fig. 2d, f) . Thus, BBR does not affect Ptd 2 Gro levels in H9c2 cells but altered its synthesis from oleate and palmitate precursors.
BBR Treatment Reduces PKCδ Activation in H9c2 Cardiac Myocytes
PKCδ activation is known to inhibit F(1)F(0) ATPase activity in neonatal cardiac mitochondria through binding to the d subunit of F(1)F(0) ATPase and this may be modulated by diacylglycerol (DAG), phosphatidylserine and Ptd 2 Gro [11] . DAG levels may be elevated in H9c2 cells treated with palmitate [9] . It was unknown if BBR altered palmitatemediated PKCδ activation in mammalian cells. H9c2 cells were incubated with 25 µM BBR in the absence or presence of 0.1 mM palmitic acid bound to albumin (1:1 molar ratio) and PKCδ association with cell membranes determined. Treatment of H9c2 cells with BBR resulted in a reduction of PKCδ association with cell membranes compared to control (Fig. 3) . In addition, BBR treatment reduced the palmitate-mediated increase in PKCδ association with cell membranes. Thus, BBR inhibits PKCδ activation in H9c2 cardiac myocytes cells.
Discussion
In the current study, we examined if BBR inhibited OCR in H9c2 cells through alteration in Ptd 2 Gro metabolism. The principal findings of our study are (1) BBR inhibits both basal and fatty-acid mediated OCR in a concentrationdependent manner in H9c2 cells, (2) BBR does not alter Ptd 2 Gro pool size but alters its synthesis from fatty acid precursors and (3) BBR reduces PKCδ activation and fatty acid-mediated PKCδ activation.
A previous study showed that 20 µM BBR inhibited Complex I-linked respiration in C2C12 myotubes [12] . In agreement with that study, we observed a concentrationdependent decrease in OCR in H9c2 cardiac myocytes. Concentrations as low as 1 µM were sufficient to potently inhibit cellular OCR. In addition, all concentrations of BBR examined (1-50 µM) inhibited the oleic acid-mediated increase in OCR in H9c2 cells. It was previously demonstrated that BBR does not alter CPT1 protein expression in L6 myotubes [13] . Thus, the BBR-mediated reduction in fatty acid-mediated OCR was not likely due to reduced uptake of oleic acid into mitochondria. Alternatively, the reduced OCR of H9c2 cells treated with oleic acid might have been due to a reduced uptake of oleic acid into these cells. However, this did not appear to be the case since [1- 14 C]oleic acid incorporation into H9c2 cells was unaltered at all concentrations of BBR examined. Thus, BBR inhibits fatty acid mediated OCR in H9c2 cells, and this likely occurs independent of effects on fatty acid uptake.
Maintenance of Ptd 2 Gro is required for proper functioning of the mitochondrial electron transport chain (reviewed in [5, 6] that quinol-based antioxidants, including BBR, prevented peroxidation of Ptd 2 Gro liposomes [15] . Thus, if BBR treatment preserves Ptd 2 Gro through prevention of peroxidation of Ptd 2 Gro, then this might explain why reduction in mitochondrial function by BBR inhibition may be reversible in vitro.
Incubation of H9c2 cells with 0.1 mM palmitate bound to albumin (1:1 molar ratio) increased membrane-associated PKCδ. Activation of PKCδ is known to alter phospholipid scramblase-3 activity and Ptd 2 Gro distribution within mitochondria in HeLa cells and F(1)F(0) ATPase activity in neonatal cardiac mitochondria [11, 16] . We previously demonstrated in HeLa cells overexpressing phospholipid scramblase-3 or expressing a disrupted phospholipid scramblase-3 that Ptd 2 Gro synthesis was altered [17] . More recently, we demonstrated that BBR reduced DAG levels in palmitate-treated insulin resistant H9c2 cells [9] . Overexpression of wild type or a constitutively active PKCδ mutant was shown to decrease mitochondrial oxygen consumption in Mv1Lu cells [18] . In the current study, BBR treatment of H9c2 cells attenuated the palmitate-mediated increase in membrane-associated PKCδ yet still resulted in a reduction in OCR. These data provide evidence that BBR inhibits cellular OCR independent of PKCδ activation.
Our studies may have important implications for use of BBR as a therapeutic agent, as very low in vitro concentrations (1 µM) of BBR appeared to markedly inhibit OCR in H9c2 cells. Chronic administration of BBR at 15 mg/kg body weight/day for three months in humans was shown to result in a plasma concentration of 4 nM of BBR [19] . However, > 20 nM of BBR and its metabolites were found in these subjects. As bioavailability of BBR becomes increased through methods such as binding with sodium caprate [20] , increased plasma concentrations of BBR and its metabolites may have the potential to inhibit cellular OCR in mammalian tissues. We suggest that mitochondrial respiratory function should be closely monitored with the use of BBR as an antidiabetic agent.
